Searched for
MANKIND PHARMA Q2 EXPECTATIONS
Q1 earnings preview: Here’s what Nomura expects from Nestle, Titan, other consumer majors’ June quarter resultsNomura expects consumer staples to deliver a strong start to FY27, forecasting double-digit sales growth for several companies in the June ...- International visitors to Dubai to return ahead of hotel rate recoveryDubai's tourism is bouncing back, with visitor numbers expected to recover before hotel rates. Accor, a major hospitality player, notes a l...
- Goldman Sachs upgrades India's growth outlook after US-Iran peace dealGoldman Sachs has raised India's 2026 real GDP growth forecast to 6.8% from 6.5%, citing lower oil prices, easing supply disruptions and re...
- Pharma, power & mid-sized banks: Where Mayuresh Joshi is putting money to work right nowIndian markets are showing signs of recovery as geopolitical tensions ease, paving the way for a stronger earnings outlook in the second ha...
- Brokerages stay bullish on Laurus Labs as CDMO momentum and margins improveLaurus Labs' stock has surged 30% on robust FY26 results, fueled by a booming contract manufacturing business and improved product mix. The...
- Cooling crude prices drive weekly gains; Street expects Q2 earnings recoveryIndian stock markets closed slightly higher on Thursday, marking a third consecutive week of gains, buoyed by falling crude oil prices. The...
- Oil slide powers India's stock benchmarks to longest weekly winning run 7 monthsIndian stock markets achieved their longest winning streak in seven months, with the Nifty 50 and BSE Sensex closing higher. Falling crude ...
- India's CDMO industry set for global shift as pharma diversifies beyond China: Sai Life SciencesIndian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like S...
- Buy, Sell or Hold: Goldman Sachs maintains sell on Bharat Dynamics; HDFC Securities maintains buy on IndiaMART InterMESHBrokerages remain divided on two stocks. Goldman Sachs retained its 'Sell' rating on Bharat Dynamics, raising the target price marginally t...
- Honasa Consumer to buy 58% stake in Fluence Pharma at Rs 135-crore enterprise valueMamaearth's parent company, Honasa Consumer, is acquiring a majority stake in nutraceuticals brand Fluence Pharma for ₹135 crore. This stra...
- Ahead of Market: 10 things that will decide stock market action on WednesdaySensex and Nifty plunged over 1% on Tuesday amid global market weakness, IT sector losses, a weaker rupee and fresh foreign fund outflows. ...
- Honasa Consumer to acquire majority stake in Fluence Pharma at Rs 135-crore valuationHonasa Consumer has secured a majority stake in Mumbai's hair therapy brand Fluence Pharma for Rs 135 crore. This move marks the company's ...
- Honasa Consumer enters nutraceuticals segment; to acquires 58 pc stake in Fluence PharmaHonasa Consumer, parent of Mamaearth, is acquiring a 58% stake in nutraceuticals firm Fluence Pharma for Rs 135 crore, marking its entry in...
- Healthium Medtech CEO Anish Bafna steps down, moves to non-executive chairman roleHealthium Medtech's CEO Anish Bafna is transitioning to non-executive chairman as KKR-owned company seeks a new chief within a month. Bafna...
- Meesho shares rise 2% as Citi initiates coverage with Buy rating. Here's whyInternational brokerage Citi initiated coverage on Meesho with a 'Buy' rating, setting a target price of Rs 210 and anticipating a 23% upsi...
- RBI seen in no rush to press rate hike pedal, decision may get deferred to second half of FY27Economists are increasingly pushing back expectations of a Reserve Bank of India (RBI) interest rate hike, with many now seeing any tighten...
- Bharat Electronics shares in focus after defence PSU wins orders worth Rs 1,081 croreBharat Electronics shares are in focus following a significant Rs 1,081 crore order win, adding to previous gains. The defence PSU reported...
- Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...
- Health insurance: Overall claims experience needs improvement in India; delays, rejections are big pain points in reimbursement, says surveyPolicybazaar's latest Health Claims Experience Index reveals that while cashless claims are preferred, the overall process needs significan...
- Sun Pharma adds Innovcare to its fold in Rs 271.2 crore all-cash transactionIndia's largest drugmaker, Sun Pharma, is set to acquire Mumbai-based Innovcare Lifesciences for approximately $28.7 million in an all-cash...
Load More
